DIARRHOEA is the #7 most commonly reported adverse reaction for DARATUMUMAB, manufactured by Janssen Biotech, Inc.. There are 1,639 FDA adverse event reports linking DARATUMUMAB to DIARRHOEA. This represents approximately 2.7% of all 59,976 adverse event reports for this drug.
Patients taking DARATUMUMAB who experience diarrhoea should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
Reporting Frequency
DIARRHOEA1,639 of 59,976 reports
DIARRHOEA is a less commonly reported adverse event for DARATUMUMAB, but still significant enough to appear in the safety profile.
Other Side Effects of DARATUMUMAB
In addition to diarrhoea, the following adverse reactions have been reported for DARATUMUMAB:
DIARRHOEA has been reported as an adverse event in 1,639 FDA reports for DARATUMUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
How common is DIARRHOEA with DARATUMUMAB?
DIARRHOEA accounts for approximately 2.7% of all adverse event reports for DARATUMUMAB, making it a notable side effect.
What should I do if I experience DIARRHOEA while taking DARATUMUMAB?
If you experience diarrhoea while taking DARATUMUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.
Disclaimer: This analysis is based on FDA adverse event reports and is for informational purposes only. Reports do not prove causation. Always consult your healthcare provider.